An interventional study of Disposable Noninvasive Skin Closure Device (Shanghai Zhizhong Medical Technology Co., Ltd. Catalog No.: 240430PFF) in Scar, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Cicatrix with a site in China — 9 open to participants now, 9 under way, none of them phase 3. Cicatrix · China.
Among the 42 studies in Cicatrix with a site in China, this one is the 29th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 23 with no phase, and was the 40th registered.
613 studies on the registry are indexed under Cicatrix; 115 are open to participants now.
Browse Cicatrix studies →9 of the 42 studies in Cicatrix with a site in China are open now. Recruiting first, the newest first:
Mabwell (Shanghai) Bioscience Co., Ltd. · Sites in China
Ages 18+
Women's Hospital School Of Medicine Zhejiang University · Sites in China
Ages 18+ · Women only
LIAO Peng · Sites in China
Ages 3–6
First Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages up to 80
Chinese Medical Association · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 20 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 2
First in 2011; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 25 is below the median of 40 across 514 interventional studies indexed under Cicatrix.
Median enrollment 50 across the 34 interventional studies, 119 across the 8 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 42 have an industry lead sponsor. The 10 most frequent:
Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 276 are open to participants now.
Peking University Third Hospital has 1 study filed under Cicatrix — fewer than ten, so there is no comparison to draw.
4 of the studies in Cicatrix with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07576608Mabwell (Shanghai) Bioscience Co., Ltd.A Phase II Study of 9MW3811 in Patients With Pathological Scar | 2026-12 |
| NCT07608094Women's Hospital School Of Medicine Zhejiang UniversityThe Treatment Outcomes of Cesarean Scar Pregnancy | 2026-12-31 |
| NCT07620769CLASSYS Inc.Safety and Efficacy Evaluation of the Radiofrequency Therapeutic Device for the Treatment of Atrophic Acne Scars | 2027-03 |
| NCT07849010Peking University Third HospitalDisposable Noninvasive Skin Closure for Promoting Postoperative Wound Healing and Preventing Surgical Skin Scarring | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 42 studies in Cicatrix with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of a disposable noninvasive skin closure device in promoting postoperative wound healing and reducing surgical scar formation. Participants will receive the device on one half of the surgical incision, with the other half serving as a control. Wound healing and scar appearance will be assessed during follow-up visits after surgery.
Surgical wounds can heal with visible scars. Tension on the skin may affect wound healing and scar formation. This study will evaluate whether a disposable noninvasive skin closure device can improve healing and reduce scar formation after plastic surgery.
Adults undergoing plastic surgery with an incision longer than 2 cm on the cheek, neck, trunk, or limbs will be enrolled. Each participant's incision will be divided into two parts. By random assignment, the device will be applied to one part of the incision, while the other part will receive standard postoperative care without the device. This within-participant comparison allows each participant to serve as their own control.
Participants will return for assessments at 1, 3, and 6 months after surgery. Blinded plastic surgeons will assess wound healing and scar appearance using standardized scar-rating tools. The study will evaluate whether the device is safe and effective for supporting postoperative wound healing and preventing surgical scar formation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The disposable noninvasive skin closure device will be applied to the randomly assigned half of the surgical incision for 3 months after surgery.
Device: Disposable Noninvasive Skin Closure Device (Shanghai Zhizhong Medical Technology Co., Ltd. Catalog No.: 240430PFF)
The other half of the same surgical incision will receive routine postoperative care without the disposable noninvasive skin closure device.
A disposable noninvasive skin closure device will be applied to the randomly assigned half of each participant's surgical incision after routine suturing. The device is designed to reduce tension across the skin surface without penetrating the skin. It will be used continuously for 3 months after surgery, while the other half of the incision will receive routine postoperative care without tension-reduction treatment.
Vancouver Scar Scale (VSS) score
Blinded plastic surgeons will assess each half of the surgical incision using the VSS. Lower scores indicate a better scar outcome.
Time frame: 6 months after surgery
Modified Patient and Observer Scar Assessment Scale (mPOSAS) score
Blinded plastic surgeons will assess scar appearance for each half of the surgical incision using the mPOSAS. Lower scores indicate a better scar outcome.
Time frame: 1, 3, and 6 months after surgery
Device-related adverse events
Skin redness, itching, and other adverse events related to use of the disposable noninvasive skin closure device will be recorded.
Time frame: 1, 3, and 6 months after surgery
Plan to share: No — IPD will not be shared because the study involves identifiable clinical photographs and sensitive personal health information. To protect participant privacy and confidentiality, individual participant data will remain restricted to the study team.
Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.
Of 174 non-industry interventional studies with no phase under Cicatrix, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 8 months is below that.
Counting every sponsor, half of 207 studies reached it within 18 months; a quarter within 8 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital →